 |
5 Products |  |
16 Diseases | | 5 Products |
|
3 Trials |  |
115 News |  |
- || HER-096 / Herantis
New P1 trial: Clinical Study of HER-096 in Healthy Volunteer Subjects and Patients with Parkinson's Disease (clinicaltrials.gov) - Oct 27, 2024
P1, N=40, Recruiting, Sponsor: Herantis Pharma Plc.
- | Cerebral dopamine neurotrophic factor (CDNF) / Herantis
Journal: Structural basis of CDNF interaction with the UPR regulator GRP78. (Pubmed Central) - Sep 20, 2024
Finally, mutating the key residues of CDNF mediating its interaction with GRP78 not only results in impaired binding of CDNF but also abolishes the neuroprotective activity of CDNF-derived peptides in mesencephalic neuron cultures. These results suggest that the molecular interaction with GRP78 mediates the neuroprotective actions of CDNF and provide a structural basis for development of next generation CDNF-based therapeutic compounds against neurodegenerative diseases.
- || Lymfactin (adAptVEGF-C adenoviral vector) / Herantis
Clinical, P2 data, Journal: Phase II study shows potential benefit of adenoviral vascular endothelial growth factor C (VEGF-C) and lymph node transfer in lymphedema. (Pubmed Central) - Aug 13, 2024
This study was one of the few studies to objectively show a positive effect of VLNT in a prospective clinical multicenter setting. It was also the first-ever randomized prospective clinical study showing a quantitatively positive effect of a medical therapy on the edema of lymphedema although failing to show differences between groups in primary outcome measures.
- | HER-096 / Herantis
Journal: Brain-penetrating neurotrophic factor mimetics: HER-096 as a disease-modifying therapy for Parkinson's disease. (Pubmed Central) - Jul 11, 2024
It was also the first-ever randomized prospective clinical study showing a quantitatively positive effect of a medical therapy on the edema of lymphedema although failing to show differences between groups in primary outcome measures. No abstract available
- ||| HER-096 / Herantis
Trial completion: Single Ascending Doses of HER-096 in Healthy Subjects (clinicaltrials.gov) - Oct 27, 2023
P1, N=60, Completed, Sponsor: Herantis Pharma Plc.
No abstract available Recruiting --> Completed
- || Cerebral dopamine neurotrophic factor (CDNF) / Herantis
Clinical, P1 data, Journal: Intraputamenal Cerebral Dopamine Neurotrophic Factor in Parkinson's Disease: A Randomized, Double-Blind, Multicenter Phase 1 Trial. (Pubmed Central) - Jul 31, 2023
Recruiting --> Completed Intraputamenally administered CDNF was safe and well tolerated, and possible signs of biological response to the drug were observed in individual patients.
- ||| HER-096 / Herantis
New P1 trial: Single Ascending Doses of HER-096 in Healthy Subjects (clinicaltrials.gov) - Jun 22, 2023
P1, N=60, Recruiting, Sponsor: Herantis Pharma Plc.
- ||| Lymfactin (adAptVEGF-C adenoviral vector) / Herantis
Trial termination, Combination therapy, Viral vector: A Phase I Study With Lymfactin (clinicaltrials.gov) - Apr 24, 2023
P1, N=15, Terminated, Sponsor: Herantis Pharma Plc.
Intraputamenally administered CDNF was safe and well tolerated, and possible signs of biological response to the drug were observed in individual patients. Active, not recruiting --> Terminated; Lack of efficacy
- HER-096 / Herantis
HER-096 IS A NOVEL BRAIN-PENETRATING PEPTIDOMIMETIC THAT PROMOTES PROTEOSTASIS AND REDUCES NEUROINFLAMMATION IN AGED MOUSE MODEL OF SYNUCLEINOPATHY (EXHIBITION) - Dec 23, 2022 - Abstract #ADPD2023ADPD_1994;
A more patient -friendl y route of administration will support further development of a disease - modifying therapy for PD and allow access to earlier stage patients. We conclude that HER -096, a CDNF -derived peptidomimetic, is a novel candidate for disease -modification in Parkinson 's disease.
- || Lymfactin (adAptVEGF-C adenoviral vector) / Herantis
P1 data, Clinical Trial,Phase I, Journal: Phase 1 Lymfactin® Study: 24-month Efficacy and Safety Results of Combined Adenoviral VEGF-C and Lymph Node Transfer Treatment for Upper Extremity Lymphedema. (Pubmed Central) - Nov 2, 2022
During 24 months' of follow-up, the results indicate that Lymfactin® is well tolerated. The most promising findings were a 46% reduction in excess arm volume and a nonsignificant volume increase after garment removal at 12 months, suggesting that there is potential for the reduction of lymphedema.
- | Cerebral dopamine neurotrophic factor (CDNF) / Herantis
Preclinical, Journal: Cerebral Dopamine Neurotrophic Factor Reduces α-Synuclein Aggregation and Propagation and Alleviates Behavioural Alterations in vivo. (Pubmed Central) - Feb 9, 2022
CDNF's beneficial effects on rodent behaviour appear not to be related to amount of inclusions formed in the current context and further study of its effects on the aggregation mechanism in vivo are needed. Nonetheless, the interaction of CDNF with α-synuclein, modifying its aggregation, spreading, and associated behavioural alterations, provide novel insights into the potential of CDNF as a therapeutic strategy in PD and other synucleinopathies.
- | HER-096 / Herantis
CEO transition; Herantis to focus on HER-096 https://t.co/KoqqMIOD23 (Twitter) - Jan 20, 2022
- | Cerebral dopamine neurotrophic factor (CDNF) / Herantis
Nanoform technology delivers successful results for Herantis CDNF drug candidate https://t.co/ohlpHwbR0d (Twitter) - Sep 8, 2021
- ||| Cerebral dopamine neurotrophic factor (CDNF) / Herantis
Preclinical: Herantis Pharma Announces xCDNF Preclinical Candidate Selection https://t.co/IvnTdi5pXF (Twitter) - May 30, 2021
- | Cerebral dopamine neurotrophic factor (CDNF) / Herantis
#HerantisPharma to focus on #CDNF and #xCDNF programs https://t.co/jPJn37kDRR (Twitter) - Apr 2, 2021
- || Cerebral dopamine neurotrophic factor (CDNF) / Herantis
Herantis Pharma to focus on CDNF and xCDNF programs https://t.co/bPqLImSTFk (Twitter) - Mar 29, 2021
- | Cerebral dopamine neurotrophic factor (CDNF) / Herantis
Enrollment closed: Long-Term Follow-up Safety After DDS Implantation With/Without CDNF Infusions (clinicaltrials.gov) - Mar 22, 2021
P1/2, N=15, Active, not recruiting, Sponsor: Renishaw
Nonetheless, the interaction of CDNF with α-synuclein, modifying its aggregation, spreading, and associated behavioural alterations, provide novel insights into the potential of CDNF as a therapeutic strategy in PD and other synucleinopathies. Enrolling by invitation --> Active, not recruiting
- Cerebral dopamine neurotrophic factor (CDNF) / Herantis
[VIRTUAL] PHASE I-II FIRST-IN-MAN CLINICAL TRIAL OF INTRAPUTAMENAL CDNF IN PARKINSON’S DISEASE: EXPLORATORY FLUID-BASED BIOMARKER ENDPOINTS OF THE 12-MONTH TREATMENT PERIOD () - Dec 24, 2020 - Abstract #ADPD2021ADPD_1374;
Enrolling by invitation --> Active, not recruiting The results from these exploratory CSF analyses are expected to provide further insight into the biological responses to intraputamenal CDNF infusions in PD patients.
- | Cerebral dopamine neurotrophic factor (CDNF) / Herantis
Nanoform and Herantis partner to look for opportunities to enhance BBB penetration of CDNF and xCDNF molecules https://t.co/rc36wpGW7E (Twitter) - Dec 17, 2020
- || Lymfactin (aadAptVEGF-C adenoviral vector) / Herantis
Clinical, P1 data, Journal: Phase 1 Lymfactin Study: Short-term Safety of Combined Adenoviral VEGF-C and Lymph Node Transfer Treatment for Upper Extremity Lymphedema. (Pubmed Central) - Nov 18, 2020
The study continues with a 36-months efficacy and 5 years safety follow-up of the patients. The oncological safety aspects of Lymfactin will require a longer follow-up period.
- || Cerebral dopamine neurotrophic factor (CDNF) / Herantis
Trial completion: Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study (clinicaltrials.gov) - Aug 12, 2020
P1/2, N=15, Completed, Sponsor: Herantis Pharma Plc.
The oncological safety aspects of Lymfactin will require a longer follow-up period. Active, not recruiting --> Completed
- || Cerebral dopamine neurotrophic factor (CDNF) / Herantis
New P1/2 trial: Long-Term Follow-up Safety After DDS Implantation With/Without CDNF Infusions (clinicaltrials.gov) - Jan 13, 2020
P1/2, N=16, Enrolling by invitation, Sponsor: Renishaw
- || Cerebral dopamine neurotrophic factor (CDNF) / Herantis
Trial completion: Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease (clinicaltrials.gov) - Jan 13, 2020
P1/2, N=17, Completed, Sponsor: Herantis Pharma Plc.
Active, not recruiting --> Completed Recruiting --> Completed
- | Cerebral dopamine neurotrophic factor (CDNF) / Herantis
Enrollment closed, Trial completion date, Trial primary completion date: Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study (clinicaltrials.gov) - Jan 13, 2020
P1/2, N=15, Active, not recruiting, Sponsor: Herantis Pharma Plc.
Recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Sep 2020 --> Jun 2020 | Trial primary completion date: Mar 2020 --> Jun 2020
- | Lymfactin (adAptVEGF-C adenoviral vector) / Herantis
Enrollment closed, Combination therapy: Clinical Study With Lymfactin (clinicaltrials.gov) - Dec 20, 2019
P2, N=39, Active, not recruiting, Sponsor: Herantis Pharma Plc.
Recruiting --> Active, not recruiting | Trial completion date: Sep 2020 --> Jun 2020 | Trial primary completion date: Mar 2020 --> Jun 2020 Recruiting --> Active, not recruiting
- ||| Lymfactin (aadAptVEGF-C adenoviral vector) / Herantis
Our Lymfactin(R) poster ready for prime time at #SABCS19 ! (Twitter) - Dec 12, 2019
- | Cerebral dopamine neurotrophic factor (CDNF) / Herantis
Trial primary completion date: Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease (clinicaltrials.gov) - Nov 26, 2019
P1/2, N=17, Recruiting, Sponsor: Herantis Pharma Plc.
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2019 --> Dec 2019
- Lymfactin (aadAptVEGF-C adenoviral vector) / Herantis
Lymfactin, an investigational adenoviral gene therapy expressing VEGF-C, is currently studied in a double-blind, randomized, placebo-controlled, multicenter, phase 2 clinical study in patients suffering from breast cancer associated secondary lymphedema (BCAL) (Hall 1 - Poster Session 1) - Sep 25, 2019 - Abstract #SABCS2019SABCS_1735;
Due to the nature of the study, there are no set formal statistical hypotheses for the efficacy endpoints, but suitable inferential statistics can be used when feasible.Present accrual and target accrual:A total of 40 patients are planned to be included in the clinical study. By the end of June 2019, 15 patients have been enrolled.Contact:Outi Lahdenperä, MDCMOHerantis Pharma PlcE-mail: outi.lahdenpera@herantis.comTel: +358 40 511 3194
- || Cerebral dopamine neurotrophic factor (CDNF) / Herantis
Herantis CDNF data (Twitter) - Aug 30, 2019
- || Cerebral dopamine neurotrophic factor (CDNF) / Herantis
New P1/2 trial: Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study (clinicaltrials.gov) - Dec 14, 2018
P1/2, N=18, Recruiting, Sponsor: Herantis Pharma Plc.
- | Lymfactin (adAptVEGF-C adenoviral vector) / Herantis
New P2 trial, Combination therapy: Clinical Study With Lymfactin (clinicaltrials.gov) - Sep 5, 2018
P2, N=40, Recruiting, Sponsor: Herantis Pharma Plc.
- Lymfactin (adAptVEGF-C adenoviral vector) / Herantis
Enrollment closed, Combination therapy, Viral vector: A Phase I Study With Lymfactin (clinicaltrials.gov) - Feb 23, 2018
P1, N=15, Active, not recruiting, Sponsor: Herantis Pharma Plc.
By the end of June 2019, 15 patients have been enrolled.Contact:Outi Lahdenperä, MDCMOHerantis Pharma PlcE-mail: outi.lahdenpera@herantis.comTel: +358 40 511 3194 Recruiting --> Active, not recruiting
- | Cerebral dopamine neurotrophic factor (CDNF) / Herantis
New P1/2 trial: Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease (clinicaltrials.gov) - Sep 27, 2017
P1/2, N=18, Recruiting, Sponsor: Herantis Pharma Plc.
- |||| ProtoCure Ophthalmic (urocanic acid) / Herantis
Trial completion: Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye (clinicaltrials.gov) - Sep 9, 2015
P2, N=161, Completed, Sponsor: Herantis Pharma Plc.
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||||| ProtoCure Ophthalmic (urocanic acid) / Herantis
New P2 trial: Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye (clinicaltrials.gov) - Dec 29, 2014
P2, N=150, Recruiting, Sponsor: Herantis Pharma Plc.
- | cis-urocanic acid (cis-UCA eye drops) / Herantis
Trial completion: Safety, Tolerability and Pharmacokinetics of 0.5% and 2.5% Cis-UCA Eye Drops in Adult Healthy Volunteers (Phase I) (clinicaltrials.gov) - May 14, 2012
P1, N=37, Completed, Sponsor: Laurantis Pharma, Ltd.
Recruiting --> Completed Active, not recruiting --> Completed
- |||| tacrolimus topical / Generic mfg.
Trial completion: Investigation of the Efficacy of 2.5% and 5% Cis-urocanic Acid in Patients With Moderate or Severe Atopic Dermatitis (clinicaltrials.gov) - May 14, 2012
P2, N=159, Completed, Sponsor: BioCis Pharma Ltd
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | cis-urocanic acid (cis-UCA eye drops) / Herantis
New P1 trial: Safety, Tolerability and Pharmacokinetics of 0.5% and 2.5% Cis-UCA Eye Drops in Adult Healthy Volunteers (Phase I) (clinicaltrials.gov) - Nov 20, 2011
P1, N=37, Completed, Sponsor: Laurantis Pharma, Ltd.